HURA — TuHURA Biosciences Share News
0.000.00%
Last trade - 00:00- $131.28m
- $134.16m
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 02:40 PM
Kintara Therapeutics Inc expected to post a loss of 16 cents a share - Earnings Preview
Brief: Kintara Therapeutics Announces Issuance Of New US Patent Related To VAL-083
U.S. RESEARCH ROUNDUP- Boeing, Goldman Sachs, UnitedHealth Group
Brief: Kintara Announces Grant From Luxembourg National Research Fund And Cancer Foundation Luxembourg
Brief: Kintara Therapeutics Inc - On Dec 3, Co Received A Written Notice From Nasdaq
Brief: Kintara Announces First International Site Activation In GCAR Phase 2/3 Clinical Trial For Glioblastoma
Brief: Kintara Presents Updates On Two Phase 2 Clinical Studies At The 2021 Society For Neuro-Oncology Annual Meeting
Kintara Therapeutics Inc reports results for the quarter ended in September - Earnings Summary
Brief: Kintara Therapeutics Announces Fiscal 2022 First Quarter Financial Results
Brief: Kintara Announces Changes To Executive Leadership Team
Kintara Therapeutics Inc expected to post a loss of 14 cents a share - Earnings Preview
Kintara Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Kintara Therapeutics Inc expected to post a loss of 16 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Sonoma Pharma, Digital Brands, Altimmune
H.C. Wainwright bullish on Kintara's brain tumour therapy strength
Kintara Therapeutics Inc expected to post a loss of 17 cents a share - Earnings Preview
Brief: Kintara Announces $15.0 Million Offering Of Common Stock And Warrants Priced At A Premium To Market
Kintara Therapeutics Inc expected to post a loss of 17 cents a share - Earnings Preview